Skip to main content

Table 2 The median onset time and severity of thyroid dysfunctions between the control and immunotherapy group

From: Thyroid dysfunction in Chinese nasopharyngeal carcinoma after anti-PD-1 therapy and its association with treatment response

  

Immunotherapy

Control

P

Hypothyroidism

n

24

12

 

TSH (mIU/L) (median (range))

5.185 (0.853–48.800)

6.345 (0.608–8.120)

0.341

FT4 (pmol/L) (median (range))

15.040 (1.230–9.640)

10.860 (9.680–15.620)

0.292

onset (days) (median (range))

107 (49–137)

139 (100–159)

< 0.001

Hyperthyroidism

n

18

39

 

TSH (mIU/L) (median (range))

0.053 (0.018–0.237)

0.069 (0.010–0.465)

0.394

FT4 (pmol/L) (median (range))

21 (11.500–20.820)

18.27 (13.810–41.100)

0.624

onset (days) (median (range))

104 (60–148)

112 (27–169)

0.847

  1. Abbreviations: TSH thyroid-stimulating hormone, FT4 free T4